British journal of clinical pharmacologyJun 22, 2018

Safety and tolerability of MEDI0382, a drug activating both GLP-1 and glucagon receptors, in a single dose given to healthy volunteers

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 29, 2026

Abstract

A total of 36 subjects received MEDI0382, with treatment-emergent adverse events occurring more frequently at doses ≥150 μg.

Adverse events related to MEDI0382 were mostly mild or moderate in severity.
The most common adverse events included vomiting, nausea, and dizziness.
A dose-dependent increase in heart rate was observed with MEDI0382 treatment.
MEDI0382 demonstrated a linear pharmacokinetic profile, with a time to maximum plasma concentration ranging from 4.50 to 9.00 hours.
The elimination half-life of MEDI0382 was between 9.54 and 12.07 hours.
No immunogenicity was detected during the study.

Simplified

AIMS: MEDI0382 is a balanced glucagon-like peptide-1/glucagon receptor dual agonist under development for the treatment of type 2 diabetes mellitus and non-alcoholic steatohepatitis. The primary objective was to assess the safety of MEDI0382 in healthy subjects.

METHODS: In this placebo-controlled, double-blind, Phase 1 study, healthy subjects (aged 18-45 years) were randomized (3:1) to receive a single subcutaneous dose of MEDI0382 or placebo after ≥8 h of fasting. The study consisted of six cohorts that received study drug at 5 μg, 10 μg, 30 μg, 100 μg, 150 μg or 300 μg. The primary objective was safety and tolerability. Secondary endpoints included assessments of pharmacokinetics and immunogenicity. All subjects were followed for up to 28 days.

RESULTS: A total of 36 subjects received MEDI0382 (n = 6 per cohort) and 12 subjects received placebo (n = 2 per cohort). Treatment-emergent adverse events (TEAEs) occurred more frequently with MEDI0382 vs. placebo, which was mostly due to an increased occurrence at MEDI0382 doses ≥150 μg. All TEAEs were mild or moderate in severity. The most common TEAEs were vomiting, nausea and dizziness. There appeared to be a dose-dependent increase in heart rate with MEDI0382 treatment. MEDI0382 showed linear pharmacokinetic profile (time to maximum plasma concentration: 4.50-9.00 h; elimination half-life: 9.54-12.07 h). No immunogenicity was observed in the study.

CONCLUSIONS: In this single-dose, Phase 1 study in healthy subjects, the safety and pharmacokinetic profiles of MEDI0382 support once-daily dosing and further clinical development of MEDI0382.

Full Text

Full text is available at the source.

View Full Text ↗

Safety and tolerability of MEDI0382, a drug activating both GLP-1 and glucagon receptors, in a single dose given to healthy volunteers

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief